Cargando…

Erlangen Score as a tool to predict progression from mild cognitive impairment to dementia in Alzheimer’s disease

BACKGROUND: The previously described and validated Erlangen Score (ES) algorithm enables interpretation of the cerebrospinal fluid (CSF) biomarkers of Alzheimer’s disease (AD), ordering them on an ordinal scale: from neurochemically normal (ES = 0) through improbable AD (ES = 1), possible AD (ES = 2...

Descripción completa

Detalles Bibliográficos
Autores principales:	Baldeiras, Inês, Santana, Isabel, Leitão, Maria João, Vieira, Daniela, Duro, Diana, Mroczko, Barbara, Kornhuber, Johannes, Lewczuk, Piotr
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2019
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6320577/ https://www.ncbi.nlm.nih.gov/pubmed/30611311 http://dx.doi.org/10.1186/s13195-018-0456-x

Ejemplares similares

Reconceptualization of the Erlangen Score for the Assessment of Dementia Risk: The ERlangen Score
por: Utz, Janine, et al.
Publicado: (2023)

Validation of the Erlangen Score Algorithm for Differential Dementia Diagnosis in Autopsy-Confirmed Subjects
por: Somers, Charisse, et al.
Publicado: (2019)

Addition of the Aβ42/40 ratio to the cerebrospinal fluid biomarker profile increases the predictive value for underlying Alzheimer’s disease dementia in mild cognitive impairment
por: Baldeiras, Inês, et al.
Publicado: (2018)

Lower CSF Amyloid-Beta(1–42) Predicts a Higher Mortality Rate in Frontotemporal Dementia
por: Vieira, Daniela, et al.
Publicado: (2019)

Prognosis of Early-Onset vs. Late-Onset Mild Cognitive Impairment: Comparison of Conversion Rates and Its Predictors
por: Tábuas-Pereira, Miguel, et al.
Publicado: (2016)

Clinical significance of fluid biomarkers in Alzheimer’s Disease
por: Lewczuk, Piotr, et al.
Publicado: (2020)

Validation of the Erlangen Test of Activities of Daily Living in Persons with Mild Dementia or Mild Cognitive Impairment (ETAM)
por: Luttenberger, Katharina, et al.
Publicado: (2016)

Biomarkers for the Diagnosis of Alzheimer’s Disease in Clinical Practice: The Role of CSF Biomarkers during the Evolution of Diagnostic Criteria
por: Dulewicz, Maciej, et al.
Publicado: (2022)

Neuropsychological features of progranulin-associated frontotemporal dementia: a nested case-control study
por: Lima, Marisa, et al.
Publicado: (2020)

The Erlangen test of activities of daily living in persons with mild dementia or mild cognitive impairment (ETAM) – an extended validation
por: Book, Stephanie, et al.
Publicado: (2018)

Alzheimer’s Disease—Biochemical and Psychological Background for Diagnosis and Treatment
por: Beata, Bocwinska-Kiluk, et al.
Publicado: (2023)

Cellular Receptors of Amyloid β Oligomers (AβOs) in Alzheimer’s Disease
por: Mroczko, Barbara, et al.
Publicado: (2018)

Patients with progranulin mutations overlap with the progressive dysexecutive syndrome: towards the definition of a frontoparietal dementia phenotype
por: Tábuas-Pereira, Miguel, et al.
Publicado: (2020)

Incremental value of biomarker combinations to predict progression of mild cognitive impairment to Alzheimer’s dementia
por: Frölich, Lutz, et al.
Publicado: (2017)

Le programme d'Erlangen
por: Klein, Felix
Publicado: (1974)

Clinical validation of the Lumipulse G cerebrospinal fluid assays for routine diagnosis of Alzheimer’s disease
por: Leitão, Maria João, et al.
Publicado: (2019)

Risk analysis for radiotherapy at the Universitätsklinikum Erlangen
por: Lohmann, Daniel, et al.
Publicado: (2022)

Combined Analysis of CSF Tau, Aβ42, Aβ1–42% and Aβ1–40(ox)% in Alzheimer's Disease, Dementia with Lewy Bodies and Parkinson's Disease Dementia
por: Bibl, Mirko, et al.
Publicado: (2010)

Don’t forget about tau: the effects of ApoE4 genotype on Alzheimer’s disease cerebrospinal fluid biomarkers in subjects with mild cognitive impairment—data from the Dementia Competence Network
por: Benson, Gloria S., et al.
Publicado: (2022)

CSF amyloid-β-peptides in Alzheimer's disease, dementia with Lewy bodies and Parkinson's disease dementia
por: Bibl, Mirko, et al.
Publicado: (2006)

The Road to Personalized Medicine in Alzheimer’s Disease: The Use of Artificial Intelligence
por: Silva-Spínola, Anuschka, et al.
Publicado: (2022)

Cerebrospinal fluid α synuclein concentrations in patients with positive AD biomarkers and extrapyramidal symptoms
por: Winkel, Izabela, et al.
Publicado: (2021)

A Comparison of Operational Definitions for Mild Cognitive Impairment
por: Polcher, Alexandra, et al.
Publicado: (2022)

Perfusion Imaging with SPECT in the Era of Pathophysiology-Based Biomarkers for Alzheimer's Disease
por: Weih, Markus, et al.
Publicado: (2010)

Pulsed Arterial Spin Labeling and Segmented Brain Volumetry in the Diagnostic Evaluation of Frontotemporal Dementia, Alzheimer’s Disease and Mild Cognitive Impairment
por: Marterstock, Dominique Cornelius, et al.
Publicado: (2022)

Report on a Visit to Max Planck-Institute, Munich, and Siemens Erlangen
por: Tallgren, U
Publicado: (1961)

Account of Professor Reich of Erlangen's Treatment of Febrile Diseases with Mineral Acids
Publicado: (1801)

Interprofessional education in Erlangen: A needs analysis and the conceptual work of a student working group
por: Konietzko, Raffael, et al.
Publicado: (2016)

Interlaboratory proficiency processing scheme in CSF aliquoting: implementation and assessment based on biomarkers of Alzheimer’s disease
por: Lewczuk, Piotr, et al.
Publicado: (2018)

Cerebrospinal Fluid Cortisol and Dehydroepiandrosterone Sulfate, Alzheimer’s Disease Pathology, and Cognitive Decline
por: Ouanes, Sami, et al.
Publicado: (2022)

Séminaire Lotharingien de Combinatoire : Bayreuth, Erlangen, Strasbourg : 21e Session
por: Berker, A N
Publicado: (1990)

Cognitive Blackouts in Mild Cognitive Impairment and Alzheimer's Dementia
por: Adler, Georg, et al.
Publicado: (2018)

Clinical Dementia Rating Orientation Score as an Excellent Predictor of the Progression to Alzheimer's Disease in Mild Cognitive Impairment
por: Kim, Jee Wook, et al.
Publicado: (2017)

Distributions of Aβ42 and Aβ42/40 in the Cerebrospinal Fluid in View of the Probability Theory
por: Lewczuk, Piotr, et al.
Publicado: (2021)

Long-Term Exercise and Risk of Metabolic and Cardiac Diseases: The Erlangen Fitness and Prevention Study
por: Kemmler, Wolfgang, et al.
Publicado: (2013)

Analysis of Surface Levels of IL-1 Receptors and Macrophage Scavenger Receptor I in Peripheral Immune Cells of Patients With Alzheimer Disease
por: Spitzer, Philipp, et al.
Publicado: (2019)

Exome Sequencing of a Portuguese Cohort of Frontotemporal Dementia Patients: Looking Into the ALS-FTD Continuum
por: Tábuas-Pereira, Miguel, et al.
Publicado: (2022)

Reconsidering the role of blood-brain barrier in Alzheimer’s disease: From delivery to target
por: Sousa, João André, et al.
Publicado: (2023)

Comment on “Clinical Dementia Rating Orientation Score as an Excellent Predictor of the Progression to Alzheimer's Disease in Mild Cognitive Impairment”
por: Kawada, Tomoyuki
Publicado: (2018)

Plasma neurofilament light as a potential biomarker of neurodegeneration in Alzheimer’s disease
por: Lewczuk, Piotr, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_hr0m2q2739v0n0p9pp31i78kna